Logo image of ALT

ALTIMMUNE INC (ALT) Stock Price, Quote, News and Overview

NASDAQ:ALT - Nasdaq - US02155H2004 - Common Stock - Currency: USD

5.36  +0.33 (+6.56%)

After market: 5.3499 -0.01 (-0.19%)

ALT Quote, Performance and Key Statistics

ALTIMMUNE INC

NASDAQ:ALT (5/7/2025, 8:00:00 PM)

After market: 5.3499 -0.01 (-0.19%)

5.36

+0.33 (+6.56%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High11.16
52 Week Low3.55
Market Cap412.77M
Shares77.01M
Float76.40M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-08 2025-05-08/bmo
IPO10-06 2005-10-06


ALT short term performance overview.The bars show the price performance of ALT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40

ALT long term performance overview.The bars show the price performance of ALT in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20 -20 30

The current stock price of ALT is 5.36 USD. In the past month the price increased by 46.05%. In the past year, price decreased by -25.76%.

ALTIMMUNE INC / ALT Daily stock chart

ALT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.31 332.73B
AMGN AMGEN INC 13.29 148.31B
GILD GILEAD SCIENCES INC 12.78 123.13B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.78B
REGN REGENERON PHARMACEUTICALS 12.66 60.56B
ARGX ARGENX SE - ADR 327.86 38.04B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 35.97B
ONC BEIGENE LTD-ADR N/A 25.03B
BNTX BIONTECH SE-ADR N/A 22.31B
NTRA NATERA INC N/A 21.77B
SMMT SUMMIT THERAPEUTICS INC N/A 18.04B
BIIB BIOGEN INC 7.41 17.17B

About ALT

Company Profile

ALT logo image Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 59 full-time employees. The company went IPO on 2005-10-06. The firm is focused on developing next-generation peptide-based therapeutics. The company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The firm has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The firm also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Company Info

ALTIMMUNE INC

910 Clopper Road, Suite 201S

Gaithersburg MARYLAND 20878 US

CEO: Vipin K. Garg

Employees: 59

ALT Company Website

ALT Investor Relations

Phone: 12406541450

ALTIMMUNE INC / ALT FAQ

What is the stock price of ALTIMMUNE INC today?

The current stock price of ALT is 5.36 USD. The price increased by 6.56% in the last trading session.


What is the ticker symbol for ALTIMMUNE INC stock?

The exchange symbol of ALTIMMUNE INC is ALT and it is listed on the Nasdaq exchange.


On which exchange is ALT stock listed?

ALT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ALTIMMUNE INC stock?

12 analysts have analysed ALT and the average price target is 22.29 USD. This implies a price increase of 315.94% is expected in the next year compared to the current price of 5.36. Check the ALTIMMUNE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ALTIMMUNE INC worth?

ALTIMMUNE INC (ALT) has a market capitalization of 412.77M USD. This makes ALT a Small Cap stock.


How many employees does ALTIMMUNE INC have?

ALTIMMUNE INC (ALT) currently has 59 employees.


What are the support and resistance levels for ALTIMMUNE INC (ALT) stock?

ALTIMMUNE INC (ALT) has a support level at 5.02 and a resistance level at 5.65. Check the full technical report for a detailed analysis of ALT support and resistance levels.


Is ALTIMMUNE INC (ALT) expected to grow?

The Revenue of ALTIMMUNE INC (ALT) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ALT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ALTIMMUNE INC (ALT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ALTIMMUNE INC (ALT) stock pay dividends?

ALT does not pay a dividend.


When does ALTIMMUNE INC (ALT) report earnings?

ALTIMMUNE INC (ALT) will report earnings on 2025-05-08, before the market open.


What is the Price/Earnings (PE) ratio of ALTIMMUNE INC (ALT)?

ALTIMMUNE INC (ALT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.34).


What is the Short Interest ratio of ALTIMMUNE INC (ALT) stock?

The outstanding short interest for ALTIMMUNE INC (ALT) is 29.37% of its float. Check the ownership tab for more information on the ALT short interest.


ALT Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ALT. When comparing the yearly performance of all stocks, ALT is a bad performer in the overall market: 79.45% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ALT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ALT. While ALT has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALT Financial Highlights

Over the last trailing twelve months ALT reported a non-GAAP Earnings per Share(EPS) of -1.34. The EPS increased by 6.94% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -68.24%
ROE -76.97%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%-86.49%
EPS 1Y (TTM)6.94%
Revenue 1Y (TTM)-95.32%

ALT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to ALT. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of -10.3% and a revenue growth -100% for ALT


Ownership
Inst Owners58.24%
Ins Owners0.93%
Short Float %29.37%
Short Ratio8.58
Analysts
Analysts81.67
Price Target22.29 (315.86%)
EPS Next Y-10.3%
Revenue Next Year-100%